YAP1 and neoplasm: Should MYC alterations prove common in patients whose tumours progress on treatment RAS(ON) multi-selective inhibition, combined targeting of the RAS and YAP–TAZ–TEAD pathways may provide an avenue of investigation for treating PDAC tumours with such alterations.